Roy L Hawke

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. pmc Interaction of silymarin flavonolignans with organic anion-transporting polypeptides
    Kathleen Köck
    Address Correspondence to Dr Roy L Hawke, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, 311 Pharmacy Lane, CB 7569, 3310 Kerr Hall, Chapel Hill, NC 27599 7569
    Drug Metab Dispos 41:958-65. 2013
  2. pmc Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C
    Roy L Hawke
    Clinical Assistant Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7360, Kerr Hall Rm 3310, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    J Clin Pharmacol 50:434-49. 2010
  3. pmc Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C
    Sarah J Schrieber
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599 7360, USA
    Drug Metab Dispos 39:2182-90. 2011
  4. doi request reprint The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity
    Sarah J Schrieber
    Division of Pharmacotherapy and Experimental Therapeutics, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7360, USA
    Drug Metab Dispos 36:1909-16. 2008
  5. pmc Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
    Michael W Fried
    UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
    JAMA 308:274-82. 2012
  6. doi request reprint The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans
    Katarina Ilic
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7569, Kerr Hall Rm 3310, Chapel Hill, NC 27599 7360, USA
    Drug Metab Dispos 41:575-81. 2013
  7. pmc Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)
    Sonia R Miranda
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Drug Metab Dispos 36:2219-26. 2008
  8. ncbi request reprint Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract
    Zhiming Wen
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Drug Metab Dispos 36:65-72. 2008
  9. ncbi request reprint Warfarin dosing and the promise of pharmacogenomics
    Todd E Dumas
    Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Curr Clin Pharmacol 2:11-21. 2007

Collaborators

  • Philip C Smith
  • K Rajender Reddy
  • Victor J Navarro
  • Nezam H Afdhal
  • Mei Ling Chen
  • Michael W Fried
  • Sarah J Schrieber
  • Zhiming Wen
  • Todd E Dumas
  • Katarina Ilic
  • Kathleen Köck
  • Catherine M Meyers
  • Steven H Belle
  • Edward Doo
  • Abdus S Wahed
  • Angela D M Kashuba
  • Kim L R Brouwer
  • Sonia R Miranda
  • Celeste M Lindley
  • Paul W Stewart
  • Ying Xie
  • Nicholas H Oberlies
  • Ranjit K Thirumaran
  • Erin G Schuetz
  • J Heyward Hull
  • Jin Kyung Lee
  • Manoli Vourvahis
  • Craig R Lee

Detail Information

Publications9

  1. pmc Interaction of silymarin flavonolignans with organic anion-transporting polypeptides
    Kathleen Köck
    Address Correspondence to Dr Roy L Hawke, UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill, 311 Pharmacy Lane, CB 7569, 3310 Kerr Hall, Chapel Hill, NC 27599 7569
    Drug Metab Dispos 41:958-65. 2013
    ..Higher than customary doses of silymarin, or formulations with improved bioavailability, may increase the risk of flavonolignan interactions with OATP substrates in patients...
  2. pmc Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C
    Roy L Hawke
    Clinical Assistant Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7360, Kerr Hall Rm 3310, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    J Clin Pharmacol 50:434-49. 2010
    ..1 g per day were safe and well tolerated. The nonlinear pharmacokinetics of silybin A and silybin B suggests low bioavailability associated with customary doses of silymarin may be overcome with doses above 700 mg...
  3. pmc Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C
    Sarah J Schrieber
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, Chapel Hill, NC 27599 7360, USA
    Drug Metab Dispos 39:2182-90. 2011
    ..In summary, the efficacy of silymarin may be more readily observed in NAFLD patients because of their higher flavonolignan plasma concentrations and more extensive enterohepatic cycling compared with those in HCV patients...
  4. doi request reprint The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity
    Sarah J Schrieber
    Division of Pharmacotherapy and Experimental Therapeutics, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7360, USA
    Drug Metab Dispos 36:1909-16. 2008
    ..Patients with cirrhosis had the highest plasma caspase-3/7 activity and also achieved the highest exposures for the major silymarin flavonolignans...
  5. pmc Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial
    Michael W Fried
    UNC Liver Center, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, NC 27599, USA
    JAMA 308:274-82. 2012
    ..The botanical product silymarin, an extract of milk thistle, is commonly used by patients to treat chronic liver disease, despite scant and conflicting evidence of its efficacy...
  6. doi request reprint The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans
    Katarina Ilic
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, CB 7569, Kerr Hall Rm 3310, Chapel Hill, NC 27599 7360, USA
    Drug Metab Dispos 41:575-81. 2013
    ..Prospective studies will be needed to validate the use of bupropion as a probe substrate for clinical use...
  7. pmc Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)
    Sonia R Miranda
    Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Drug Metab Dispos 36:2219-26. 2008
    ..These data indicate a primary role for Mrp2 in the biliary elimination of silymarin flavonolignan conjugates...
  8. ncbi request reprint Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract
    Zhiming Wen
    School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Drug Metab Dispos 36:65-72. 2008
    ..These data suggest that, after oral administration, silymarin flavonolignans are quickly metabolized to their conjugates, primarily forming glucuronides, and the conjugates are primary components present in human plasma...
  9. ncbi request reprint Warfarin dosing and the promise of pharmacogenomics
    Todd E Dumas
    Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7360, USA
    Curr Clin Pharmacol 2:11-21. 2007
    ..Therefore, the promise of pharmacogenomic-guided dosing as a useful strategy to improve clinical outcomes with warfarin therapy appears credible and warrants further investigation...